Wedbush Reaffirms “Outperform” Rating for Vor Biopharma (NYSE:VOR)

Wedbush reissued their outperform rating on shares of Vor Biopharma (NYSE:VOR) in a report released on Tuesday, Benzinga reports. They currently have a $11.00 price target on the stock.

Several other equities analysts have also recently issued reports on the company. Stifel Nicolaus reduced their price objective on Vor Biopharma from $15.00 to $12.00 and set a buy rating for the company in a report on Thursday, March 21st. Oppenheimer reaffirmed an outperform rating and set a $15.00 price target (down previously from $17.00) on shares of Vor Biopharma in a research note on Thursday, March 21st. JMP Securities reissued a market outperform rating and issued a $12.00 price objective on shares of Vor Biopharma in a research note on Friday, March 22nd. Finally, HC Wainwright restated a buy rating and set a $17.50 target price on shares of Vor Biopharma in a research report on Thursday, March 21st. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of Buy and an average target price of $13.50.

Vor Biopharma Stock Down 0.6 %

NYSE:VOR opened at $1.69 on Tuesday. Vor Biopharma has a fifty-two week low of $1.62 and a fifty-two week high of $5.70. The stock has a market cap of $115.29 million, a PE ratio of -0.96 and a beta of -0.36. The firm’s fifty day simple moving average is $2.01 and its 200-day simple moving average is $2.11.

Vor Biopharma (NYSE:VOR) last posted its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.10. Equities analysts anticipate that Vor Biopharma will post -1.34 earnings per share for the current year.

Hedge Funds Weigh In On Vor Biopharma

A hedge fund recently bought a new stake in Vor Biopharma stock. SG Americas Securities LLC purchased a new position in shares of Vor Biopharma Inc. (NYSE:VOR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 17,258 shares of the company’s stock, valued at approximately $37,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.